Use of ascorbyl palmitate nanostructures (ASC16) as systems for optimizing efficacy of CPG-ODN

ULLIO GAMBOA, GABRIELA; SANCHEZ VALLECILLO, MARIA FERNANDA; PALMA SANTIAGO; ALLEMANDI DANIEL; MORON GABRIEL; PISTORESI, MC; MALETTO, BELKYS

Mar del Plata

Congreso; LV Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2010

SAFE

CpG-ODN has successfully used as vaccine adjuvant but unfortunately has a reduced bioavailability. In order to improve their bioavailability we have used CpG-ODN formulated in a nanostructure of 6-O- ascorbyl palmitate (Coa-ASC16), which has the ability to form supramolecular aggregate that are produced by phase cooling below a critical micellar temperature. Previously, we have observed that this strategy increased the bioavailability considering that improved the CpG-ODN adjuvant activity. However, we still ignore the mechanisms by which Coa-ASC16 works. Perhaps more than one factor could be synergistically contributing. Here, we tested whether Coa-ASC16 “per se” is able to stimulate immune system. Mice were i.p. injected with Coa-ASC16 or without Coa-ASC16 (control group). Coa-ASC16 induced a recruitment of neutrophils (Ly6Ghigh, F4/80-, CD11b+, Ly6C+) (23±8 vs control:0.06±0.09% after two hours injection p